Newsom: California leads on prescription drugs

California regularly portrays itself as a national trendsetter on political issues, and Gov. Gavin Newsom is claiming that title on prescription drugs.

Newsom has a plan to take on the drug industry, and at an April 17 news conference in Southern California, he declared that two other governors already want to join his effort.

"California is leading the nation in holding drug companies accountable and fighting prescription drug prices," Newsom said via a press release that day, marking his 100th full day in office.

There's no question the Democratic governor is aggressively taking on the pharmaceutical industry — vowing to leverage his state's purchasing power to extract lower prices, and bluntly telling drugmakers that taxpayers are tired of being "screwed."

But Newsom's claim that California leads the nation on this issue prompted us to ask: Is that really the case?

What is Newsom doing about prescription drugs?

Newsom marked his first day in office, Jan. 7, with a direct message to the pharmaceutical industry: The nation's most populous state is fed up with the meteoric rise in prescription drug prices.

He signed an executive order directing the state to negotiate drug prices for the roughly 13 million enrollees of Medi-Cal, the country's largest Medicaid program that serves low-income residents, by 2021. And he ordered his administration to study how state agencies could band together and buy prescription drugs in bulk.

With the state buying drugs for all Medi-Cal enrollees and state entities, Newsom argues that California will leverage its purchasing power as the third-largest buyer in the country to demand lower prices from drugmakers. Eventually, Newsom envisions private purchasers — including small businesses, health plans and self-insured Californians — taking part.

Newsom has said several times he hopes this collaboration can be a model for the rest of the country.

Newsom traveled to Downey, Calif., last week to announce that Los Angeles County would join California's bulk purchasing pool, a move intended to show that others are eager to join his initiative.

How do California's efforts on prescription drugs compare with those of other states?

We interviewed five health care experts who commended Newsom for his focus on prescription drugs, but each noted that he is not the only lawmaker tackling the issue.

"Is California a leader? Yes. Is it the leader?" asked Edwin Park, a research professor at Georgetown University's Center for Children and Families. "That's not doing an assessment of what all the other states are doing."

A number of states in recent years have enacted laws to regulate pharmacy benefit managers, the so-called middlemen who negotiate with drugmakers; impose drug price transparency rules; outlaw "gag clauses" that prevent pharmacists from telling consumers about cheaper drug alternatives; and authorize the importation of drugs from Canada.

At least 28 states and the District of Columbia already participate in multistate purchasing pools — joining forces to get bigger discounts for their Medicaid programs or state employees. The Northwest Prescription Drug Consortium, formed by Oregon and Washington in 2006, invites state and local government agencies, businesses, labor unions and uninsured consumers to voluntarily pool their purchasing power.

Roughly 1.1 million people are represented by the consortium, either as individuals or through public and private entities such as the Washington State Department of Corrections, Washington's Medicaid program and SAIF Corp.

"Other states are actively looking at us as a partner," said Trevor Douglass, director of the Oregon Prescription Drug Program.

Earlier this month, Maryland lawmakers passed legislation that would create the nation's first prescription drug affordability board, which, if signed by Republican Gov. Larry Hogan, would let the state cap certain drug prices.

"There's extraordinary activity" on prescription drug prices, said Trish Riley, executive director of the National Academy for State Health Policy, which tracks bills in state legislatures around the country. "Hundreds of bills were introduced this year."

What makes California's effort novel, Newsom spokesman Nathan Click said, is the mandatory inclusion of all state agencies and the Medi-Cal program — which he said would make it the largest purchaser of drugs after Medicare and the Department of Veterans Affairs. Programs in other states are more limited, and some are voluntary.

Health care experts agreed that California's size by default makes it a national leader on the health care front, not the national leader. But if California is successful, they say, it could lower the price of drugs nationally.

Our ruling

Newsom said “California is leading the nation in holding drug companies accountable and fighting prescription drug prices."

States across the county are addressing the rising cost of prescription drugs in a variety of ways. California is not the only, or the first, one.

The scope of what Newsom is attempting could bring down drug prices for California residents, and possibly residents in other states that join the effort. But Newsom's sweeping plan is still in its infancy with many details pending, so it's too soon to gauge success.

We rate the claim HALF TRUE.

Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Telemedicine and low-carb diet slashes diabetes meds and drives lasting remission